JP2015518052A - 抗プロゲスチンの経膣送達用製剤およびその送達方法 - Google Patents
抗プロゲスチンの経膣送達用製剤およびその送達方法 Download PDFInfo
- Publication number
- JP2015518052A JP2015518052A JP2015515205A JP2015515205A JP2015518052A JP 2015518052 A JP2015518052 A JP 2015518052A JP 2015515205 A JP2015515205 A JP 2015515205A JP 2015515205 A JP2015515205 A JP 2015515205A JP 2015518052 A JP2015518052 A JP 2015518052A
- Authority
- JP
- Japan
- Prior art keywords
- capsule
- antiprogestin
- pullulan
- weight
- active agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本出願は、2012年5月31日に出願された米国特許仮出願第61/653,674号の利益を主張し、その内容が引用により本明細書により組み込まれる。
以下のカプセル用充填製剤(活性薬剤なし)をカプセルに液剤注入するために50〜70℃で液化するか、または成形して以下に記載の腔「錠」にした:
PEG 400 25.87%(賦形剤 w/w)
Wecobee M 50.1%(賦形剤 w/w)
PEG 1000 49.4%(賦形剤 w/w)
レシチン 0.5%(賦形剤 w/w)
PEG1000 100%または99.98%(賦形剤 w/w)
ブチル化ヒドロキシトルエン 0%または0.02%(賦形剤 w/w)
実施例2. 選択的プロゲステロン受容体調節薬CDB−4124の経膣送達に関する動物の薬物動態研究
実施例3. CDB−4124を有するプルランカプセルの経膣投与
Claims (21)
- 薬学的に活性な薬剤および1以上の賦形剤を含むカプセル用充填製剤を有する、プルランを含む粘膜付着性カプセルを、雌の膣粘膜に投与することを含む、前記薬学的に活性な薬剤を経粘膜投与する方法。
- 活性薬剤が抗プロゲスチン、プロゲスチン、エストロゲン、またはその組み合わせである、請求項1に記載の方法。
- 活性薬剤が抗プロゲスチンである、請求項2に記載の方法。
- 抗プロゲスチンが、子宮内膜症およびそれに関連する疼痛、腺筋症、卵巣の子宮内膜腫、月経困難症、子宮筋腫、子宮内膜過形成、卵巣癌、および子宮頸癌からなる群より選択されるプロゲステロン依存性病態を治療するために投与される、請求項3に記載の方法。
- 抗プロゲスチンの用量が、経口送達される場合の最小有効量より少ない、請求項4に記載の方法。
- 抗プロゲスチンが、0.5mg/kg〜500mg/kgの投与量で投与される、請求項1〜5のうちいずれか1項に記載の方法。
- 抗プロゲスチンが、毎日約1mg〜50mgの用量で投与される、請求項6に記載の方法。
- 抗プロゲスチンが、12.5mg以下の投与量で投与される、請求項7に記載の方法。
- 抗プロゲスチンが、CDB−4124である、請求項8に記載の方法。
- カプセルが約85〜90wt%のプルランを含む、請求項1に記載の方法。
- カプセルが、塩化カリウム1.0%〜1.5重量%、カラギーナン0.1%〜0.4重量%、1以上の界面活性剤0.1%〜0.2重量%、および水10%〜15重量%を含む、請求項10に記載の方法。
- カプセルが、プルラン86.3重量%、塩化カリウム1.32重量%、カラギーナン0.27重量%、糖エステル類、モノラウリン酸ソルビタンおよびその組み合わせより選択される界面活性剤0.15重量%、および水12重量%を含む、請求項11に記載の方法。
- 充填製剤が、本質的に薬学的に活性な化合物、Gelucire44/14およびPEGからなる、請求項11に記載の方法。
- Gelucire44/14が、50%〜90w/w%の賦形剤として存在する、請求項13に記載の方法。
- 充填製剤が、薬学的に活性な化合物、ならびに約74.13%(w/w)Gelucireおよび約25.87%PEG400からなる賦形剤を含む、請求項14に記載の方法。
- 充填製剤が、本質的に薬学的に活性な化合物、ならびに30%〜60w/w%WecobeeM、30%〜60w/w%PEG1000および0.1%〜5w/w%レシチンを含む賦形剤からなる、請求項11に記載の方法。
- 充填製剤が、薬学的に活性な薬剤、およびbetween 501からなる賦形剤を含む、請求項16に記載の方法。
- 充填製剤が本質的に薬学的に活性な化合物、およびPEG1000および随意にブチル化ヒドロキシトルエンからなる、請求項11に記載の方法。
- 活性薬剤が抗プロゲスチンである、請求項10〜18のうちいずれか1項に記載の方法。
- 抗プロゲスチンがCDB−4124である、請求項19に記載の方法。
- カプセルが1日に1回投与される、請求項1〜20のうちいずれか1項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261653674P | 2012-05-31 | 2012-05-31 | |
US61/653,674 | 2012-05-31 | ||
PCT/US2013/043447 WO2013181449A1 (en) | 2012-05-31 | 2013-05-30 | Formulations and methods for vaginal delivery of antiprogestins |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015518052A true JP2015518052A (ja) | 2015-06-25 |
JP2015518052A5 JP2015518052A5 (ja) | 2016-07-14 |
JP6341910B2 JP6341910B2 (ja) | 2018-06-13 |
Family
ID=48614182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015515205A Expired - Fee Related JP6341910B2 (ja) | 2012-05-31 | 2013-05-30 | 抗プロゲスチンの経膣送達用製剤およびその送達方法 |
Country Status (23)
Country | Link |
---|---|
US (1) | US10328022B2 (ja) |
EP (1) | EP2854763B1 (ja) |
JP (1) | JP6341910B2 (ja) |
KR (1) | KR102127348B1 (ja) |
CN (1) | CN104334158B (ja) |
AU (1) | AU2013267359C1 (ja) |
BR (1) | BR112014029131B1 (ja) |
CA (1) | CA2872644A1 (ja) |
CL (1) | CL2014003232A1 (ja) |
CO (1) | CO7141411A2 (ja) |
CR (1) | CR20140567A (ja) |
EA (1) | EA030444B1 (ja) |
ES (1) | ES2701400T3 (ja) |
HK (1) | HK1206622A1 (ja) |
IL (1) | IL235450B (ja) |
IN (1) | IN2014DN10548A (ja) |
MX (2) | MX363640B (ja) |
NZ (1) | NZ702467A (ja) |
PH (1) | PH12014502516B1 (ja) |
SG (2) | SG11201407397WA (ja) |
UA (1) | UA114106C2 (ja) |
WO (1) | WO2013181449A1 (ja) |
ZA (1) | ZA201408262B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020516653A (ja) * | 2017-04-14 | 2020-06-11 | カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップCapsugel Belgium NV | プルランカプセル |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
CA2948287A1 (en) | 2014-05-05 | 2015-11-12 | Repros Therapeutics Inc. | Formulations and methods for vaginal delivery of antiprogestins |
JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然の併用ホルモン補充療法剤及び療法 |
US11623008B2 (en) * | 2014-08-20 | 2023-04-11 | Professional Compounding Centers Of America | Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan |
US20160106737A1 (en) * | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
EP3025709B1 (en) | 2014-11-27 | 2020-09-30 | Capsugel Belgium NV | Dosage form articles for external mucosal applications |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
RU2018133932A (ru) | 2016-04-01 | 2020-05-12 | Терапьютиксмд, Инк. | Фармацевтическая композиция стероидного гормона |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
WO2018189587A1 (en) | 2017-04-14 | 2018-10-18 | Capsugel Belgium Nv | Process for making pullulan |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008012281A (ja) * | 2006-06-05 | 2008-01-24 | Koritsu Shoji:Kk | 挿入補助器具 |
JP2010523594A (ja) * | 2007-04-05 | 2010-07-15 | ユニバーシティ・オブ・カンザス | プルランを含む速溶性医薬組成物 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2377418A1 (fr) | 1977-01-13 | 1978-08-11 | Roussel Uclaf | Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments |
FR2521565B1 (fr) | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
FR2522328B1 (fr) | 1982-03-01 | 1986-02-14 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments |
FR2534487B1 (fr) | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
DE3237814A1 (de) * | 1982-10-12 | 1984-04-12 | Warner-Lambert Co., 07950 Morris Plains, N.J. | Wasserfreie emulsionen und verwendung derselben |
JPH0830004B2 (ja) | 1983-11-14 | 1996-03-27 | コロンビア ラボラトリーズ インコーポレイテッド | 生物接着性組成物およびそれにより治療する方法 |
FR2598421B1 (fr) | 1986-05-06 | 1988-08-19 | Roussel Uclaf | Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
US4954490A (en) | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
US5077211A (en) | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
US5468741A (en) | 1993-05-28 | 1995-11-21 | The Regents Of The University Of California | Use of low levels of mifepristone to treat leiomyomata |
US5543150A (en) | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
TW385308B (en) * | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
DE4426601A1 (de) | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
SK282570B6 (sk) | 1995-02-02 | 2002-10-08 | Schering Aktiengesellschaft | Antagonisty progesterónu na výrobu liekov na ošetrenie dysfunkčného maternicového krvácania |
GB9522403D0 (en) * | 1995-11-01 | 1996-01-03 | Hoechst Roussel Ltd | Intravaginal drug delivery device |
HU230492B1 (hu) | 1996-05-01 | 2016-08-29 | The Government Of The United States Of America | Új progesztációt gátló szerként használható 21-helyzetben szubsztituált progeszteron-származékok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk |
US6900193B1 (en) | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
WO1998008471A1 (en) | 1996-08-30 | 1998-03-05 | The Population Council, Inc. | Vaginal application mifepristone |
US6982091B2 (en) | 2001-08-29 | 2006-01-03 | Umd, Inc. | Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy |
US6682174B2 (en) | 1998-03-25 | 2004-01-27 | Silverbrook Research Pty Ltd | Ink jet nozzle arrangement configuration |
US20050070516A1 (en) | 1997-10-28 | 2005-03-31 | Vivus Inc. | As-needed administration of an androgenic agent to enhance female desire and responsiveness |
US6020328A (en) | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
EP1008443A1 (de) | 1998-12-08 | 2000-06-14 | Alusuisse Technology & Management AG | Sterilisierbarer Folienverbund für Verpackungszwecke |
US6740645B1 (en) | 1999-09-03 | 2004-05-25 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties |
AR025609A1 (es) * | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones lipidas solidas |
UA74168C2 (uk) | 1999-10-05 | 2005-11-15 | Коламбіа Леборетеріс (Бермуда) Лімітед | Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу |
DK1265911T3 (da) | 2000-03-17 | 2008-09-29 | Us Gov Health & Human Serv | 17-alfa-substitueret-11-beta-substitueret-4-aryl og 21-substitueret 19-norpregnadiendion som antiprogestationelle midler |
IN191020B (ja) | 2000-03-28 | 2003-09-13 | Dabur Res Foundation | |
US7378406B2 (en) | 2000-10-18 | 2008-05-27 | Schering Ag | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
ES2312593T3 (es) | 2001-07-09 | 2009-03-01 | Repros Therapeutics Inc. | Procedimientos y materiales para el tratamiento de la deficiencia de testosterona en hombres. |
JP2003143474A (ja) | 2001-11-02 | 2003-05-16 | Matsushita Electric Ind Co Ltd | 映像信号処理システム |
US7417013B2 (en) | 2002-05-01 | 2008-08-26 | Mcneil-Ppc, Inc. | Warming and nonirritating lubricant compositions and method of comparing irritation |
AU2004233997C1 (en) | 2003-04-29 | 2014-01-30 | Massachusetts Institiute Of Technology | Methods and devices for the sustained release of multiple drugs |
EP1593376A1 (en) * | 2004-05-04 | 2005-11-09 | Warner-Lambert Company LLC | Improved pullulan capsules |
MX2007000273A (es) | 2004-07-09 | 2007-05-21 | Population Council Inc | Composiciones de liberacion sostenida que contiene moduladores del receptor de progesterona. |
GT200500185A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
CA3071412A1 (en) | 2005-03-22 | 2006-09-28 | Allergan Pharmaceuticals International Limited | Dosing regimes for trans-clomiphene |
JP2008536910A (ja) | 2005-04-20 | 2008-09-11 | ファイザー・リミテッド | プロゲステロン受容体アンタゴニストとしてのピラゾール誘導体 |
DE102005030294A1 (de) | 2005-06-24 | 2007-01-04 | Schering Ag | Nichtsteroidale Progesteronrezeptor-Modulatoren |
EA200800974A1 (ru) * | 2005-09-29 | 2008-10-30 | Репрос Терапьютикс Инк. | Композиции с улучшенной биодоступностью, содержащие стероидное производное и полигликолизированный глицерид |
CN1846703A (zh) | 2006-02-13 | 2006-10-18 | 程定超 | 米非司酮阴道给药制剂及其组成和制备方法 |
WO2007103510A2 (en) | 2006-03-08 | 2007-09-13 | Danco Laboratories Llc | Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders |
KR20070116538A (ko) * | 2006-06-05 | 2007-12-10 | 유겐가이샤 코리츠 쇼지 | 삽입 보조 기구 |
CZ300424B6 (cs) * | 2006-06-20 | 2009-05-13 | Pliva - Lachema A. S. | Farmaceutická kompozice pro perorální podání |
PL3263112T3 (pl) | 2006-10-24 | 2021-01-11 | Allergan Pharmaceuticals International Limited | Kompozycje i sposoby tłumienia przerostów endometrium |
EP2148681B1 (en) | 2007-04-20 | 2016-03-16 | PregLem S.A. | Selective progesterone modulators in the treatment of uterine bleeding |
JP5555631B2 (ja) | 2007-09-20 | 2014-07-23 | ラピドット メディカル インポート アンド マーケティング リミテッド | ミフェプリストンによる子宮平滑筋腫、平滑筋腫、筋腫、子宮類線維腫、子宮内膜症、または腺筋症を治療するための組成物および手段 |
TWI477276B (zh) * | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
JP5992330B2 (ja) * | 2009-09-29 | 2016-09-14 | メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ | 物質を投与するための子宮内電子カプセル |
UA113283C2 (xx) | 2010-12-23 | 2017-01-10 | 19-норстероїди і їх застосування для лікування прогестеронзалежних станів | |
DE202011110355U1 (de) | 2011-03-09 | 2014-01-15 | Arstat, Inc. | Behandlung von Uterusmyomen durch intravaginale Verabreichung einer niedrigen Dosis eines selektiven Progesteronrezeptormodulators, eines Antigestagens oder eines Antigestagen-Wirkstoffes |
UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування |
-
2013
- 2013-05-30 EA EA201492290A patent/EA030444B1/ru unknown
- 2013-05-30 US US14/403,141 patent/US10328022B2/en not_active Expired - Fee Related
- 2013-05-30 NZ NZ702467A patent/NZ702467A/en not_active IP Right Cessation
- 2013-05-30 CA CA2872644A patent/CA2872644A1/en not_active Abandoned
- 2013-05-30 IN IN10548DEN2014 patent/IN2014DN10548A/en unknown
- 2013-05-30 JP JP2015515205A patent/JP6341910B2/ja not_active Expired - Fee Related
- 2013-05-30 CN CN201380028413.4A patent/CN104334158B/zh not_active Expired - Fee Related
- 2013-05-30 MX MX2014014054A patent/MX363640B/es unknown
- 2013-05-30 ES ES13728632T patent/ES2701400T3/es active Active
- 2013-05-30 UA UAA201414106A patent/UA114106C2/uk unknown
- 2013-05-30 SG SG11201407397WA patent/SG11201407397WA/en unknown
- 2013-05-30 WO PCT/US2013/043447 patent/WO2013181449A1/en active Application Filing
- 2013-05-30 SG SG10201704858PA patent/SG10201704858PA/en unknown
- 2013-05-30 AU AU2013267359A patent/AU2013267359C1/en not_active Ceased
- 2013-05-30 KR KR1020147032210A patent/KR102127348B1/ko active IP Right Grant
- 2013-05-30 BR BR112014029131-4A patent/BR112014029131B1/pt not_active IP Right Cessation
- 2013-05-30 EP EP13728632.4A patent/EP2854763B1/en active Active
-
2014
- 2014-11-02 IL IL235450A patent/IL235450B/en active IP Right Grant
- 2014-11-11 PH PH12014502516A patent/PH12014502516B1/en unknown
- 2014-11-11 ZA ZA2014/08262A patent/ZA201408262B/en unknown
- 2014-11-19 MX MX2019003467A patent/MX2019003467A/es unknown
- 2014-11-25 CO CO14259346A patent/CO7141411A2/es unknown
- 2014-11-27 CL CL2014003232A patent/CL2014003232A1/es unknown
- 2014-12-09 CR CR20140567A patent/CR20140567A/es unknown
-
2015
- 2015-07-30 HK HK15107275.4A patent/HK1206622A1/xx not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008012281A (ja) * | 2006-06-05 | 2008-01-24 | Koritsu Shoji:Kk | 挿入補助器具 |
JP2010523594A (ja) * | 2007-04-05 | 2010-07-15 | ユニバーシティ・オブ・カンザス | プルランを含む速溶性医薬組成物 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020516653A (ja) * | 2017-04-14 | 2020-06-11 | カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップCapsugel Belgium NV | プルランカプセル |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6341910B2 (ja) | 抗プロゲスチンの経膣送達用製剤およびその送達方法 | |
PT646008E (pt) | Minimizacao de hemorragias secundarias associadas a progestina | |
US20190127413A1 (en) | Compositions and Methods for Non-Toxic Delivery of Antiprogestins | |
US20200222315A1 (en) | Formulations and methods for vaginal delivery of antiprogestins | |
JP2018062530A (ja) | プロゲステロン依存性病態を処置する方法およびその組成物 | |
JP2003048836A (ja) | 効能を保持し無月経を引き起こす超低用量の経口避妊薬 | |
JP2001523639A (ja) | プロゲストゲン−抗プロゲストゲンレジメン | |
WO2018106914A1 (en) | Oral pharmaceutical compositions comprising an unmicronized selective progesterone receptor as active agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160527 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160527 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170314 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170329 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170612 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170828 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170926 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180221 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180425 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180515 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6341910 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |